Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $21.1250.

Several brokerages recently issued reports on TLX. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Citigroup upped their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th.

Insider Transactions at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch bought 34,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was bought at an average cost of $14.48 per share, for a total transaction of $499,560.00. Following the completion of the transaction, the chief executive officer owned 20,709,500 shares of the company’s stock, valued at approximately $299,873,560. The trade was a 0.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the second quarter worth $975,000. Jane Street Group LLC purchased a new position in Telix Pharmaceuticals in the second quarter worth $564,000. IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals during the second quarter valued at about $213,000. Rhumbline Advisers boosted its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals during the third quarter valued at about $243,000.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $10.09 on Friday. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $17.25. The firm’s fifty day moving average price is $10.12 and its 200-day moving average price is $8.73. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.